Speaker: Michael Mourez, Head BacteriOmics Platform, Evotec, France
Moderator: Laura Piddock, Director Scientific Affairs, GARDP
In this webinar, the following aspects were presented:
- What are the most common techniques used to measure the extent of the risk of selecting for resistance when using a novel direct-acting antibacterial. What are the advantages and limitations of these techniques?
- What are some techniques that may be used to understand the origins of resistance selection?
- How to rationalize/manage the risk of translation of the resistance selection from in vitro to the clinical settings?
The presentation was followed by a Q&A session.
* This presentation was also part of the ‘Bootcamp: Understanding the Potential for Antimicrobial Resistance in the Drug Discovery Process’, jointly organized by GARDP, CARB-X, REPAIR Impact Fund, JPIMAR and Wellcome Trust at the ASM/ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance 2019 *
This live webinar including interactive Q&A session was broadcast on 21 January 2020.
If you have questions or comments, please let us know: firstname.lastname@example.org.